Burlingame, CA – According to filings with the U.S. Securities and Exchange Commission, Inflammatix is raising $102,396,088.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Timothy Sweeney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inflammatix

Inflammatix will create and commercialize best-in-class host-response diagnostics to resolve major clinical and public health challenges. Better patient care is at the core of what we do. We achieve better patient care through our innovative approach to developing diagnosticsûour tests read the patient’s immune system to help us understand the cause of infection and the degree of its severity. Armed with this knowledge, the clinician can treat the patient appropriately and within minutes. Our expert bioinformatics and assay development teams are building a host response-based diagnostics pipeline that includes tests for acute infection and sepsis, emerging infectious diseases, autoimmune diseases, tropical infections, transplant rejection and other conditions. We are initially focused on developing tests for acute bacterial infections, viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.

To learn more about Inflammatix, visit http://inflammatix.com/

Contact:
Timothy Sweeney, Chief Executive Officer
650-443-3030
tim@inflammatix.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved